The estimated Net Worth of Peter A Kiener is at least $100 Mille dollars as of 23 March 2023. Peter Kiener owns over 9,682 units of Cue Biopharma Inc stock worth over $5,712 and over the last 9 years he sold CUE stock worth over $0. In addition, he makes $94,756 as Independent Director at Cue Biopharma Inc.
Peter has made over 3 trades of the Cue Biopharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 9,682 units of CUE stock worth $27,691 on 23 March 2023.
The largest trade he's ever made was exercising 50,000 units of Cue Biopharma Inc stock on 7 December 2017 worth over $416,500. On average, Peter trades about 2,852 units every 69 days since 2016. As of 23 March 2023 he still owns at least 9,682 units of Cue Biopharma Inc stock.
You can see the complete history of Peter Kiener stock trades at the bottom of the page.
Dr. Peter A. Kiener Ph.D. serves as Independent Director of the Company. Dr. Kiener served as the Chief Scientific Officer and Head of Research and Development of Sucampo Pharmaceuticals, Inc. (“Sucampo”), a global biopharmaceutical company, from October 2014 to February 2018. Prior to joining Sucampo, Dr. Kiener served as the Chief Scientific Officer of Ambrx, Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates from 2013 to 2014. From 2009 to 2013, he was President and co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. From 2001 to 2009, he was head of Research and R&D at MedImmune, the biologics research and development arm of AstraZeneca. Dr. Kiener holds a Bachelor’s Degree in Chemistry from the University of Lancaster and a Doctorate of Philosophy in Biochemistry from the University of Oxford. Dr. Kiener’s extensive executive leadership experience and his in-depth knowledge of the biopharmaceutical industry make him well qualified to serve on our board of directors.
As the Independent Director of Cue Biopharma Inc, the total compensation of Peter Kiener at Cue Biopharma Inc is $94,756. There are 8 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.
Peter Kiener is 68, he's been the Independent Director of Cue Biopharma Inc since 2018. There are 1 older and 18 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
Peter's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher e Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Cue Biopharma Inc executives and other stock owners filed with the SEC include: